PTC Inc. (PTC)
PTC Gearing Up to Report Q2 Earnings: Here's What to Expect
PTC's Q2 performance is likely to have benefited from momentum across its PLM and CAD solutions, though competition and tough selling environment remain concerns.
Why PTC Inc. (PTC) is Poised to Beat Earnings Estimates Again
PTC Inc. (PTC) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
PTC Inc. (PTC) Expected to Beat Earnings Estimates: Should You Buy?
PTC Inc. (PTC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PTC Expands Onshape Portfolio to Transform Product Design & Compliance
PTC introduces Onshape AI Advisor and Onshape Government for designers, engineers, educators and professionals in regulated industries.
PTC Launches Codebeamer 3.0 to Boost Speed, Quality & Sustainability
PTC launches Codebeamer 3.0 to speed up product development, boost sustainability and ensure quality and compliance with full traceability and smarter tools.
PTC Therapeutics says European Commission will remove muscle disorder drug
PTC Therapeutics said on Friday the European Commission will remove its inherited progressive muscle-wasting disorder from the region after an advisory panel reaffirmed a negative opinion of the drug in January.
PTC's Premium Valuation Justified By Strong Outlook, Buy On Dips
PTC basically offers end-to-end software solutions for managing the product lifecycle across diverse industries. Their flagship platforms are Windchill, Codebeamer, ServiceMax, and Creo, which overall help with operational efficiency and quality improvements. PTC is also quickly transitioning toward cloud-native SaaS tools. Good examples of this are their Onshape and Arena new offerings.
PTC to Showcase Windchill AI at Hannover Messe 2025: Stock to Gain?
PTC will unveil Windchill AI, Codebeamer AI and ServiceMax AI at Hannover Messe 2025, promising innovation and fostering digital transformation.
PTC Therapeutics: Upside In Rare Disease Innovation
PTC Therapeutics is poised for a potential turnaround with key FDA reviews in 2025 for vatiquinone and sepiapterin, despite past revenue declines. The company maintains a strong cash position of over $2 billion, providing a buffer as it awaits regulatory approvals to boost revenue. PTC's diversified pipeline, including vatiquinone for Friedreich's ataxia, could significantly enhance revenue if approved, targeting a $2.8 billion market.
Why Is PTC Inc. (PTC) Down 6.4% Since Last Earnings Report?
PTC Inc. (PTC) reported earnings 30 days ago. What's next for the stock?
Looking for Sneaky Growth? These 2 Stocks Are Low-Key Buys for 2025.
Sometimes, the headline numbers don't tell the whole story. That's definitely the case with industrial software company PTC (PTC 0.05%) and workflow technology company Trimble (TRMB 1.11%).
Here's Why PTC Stock Declined This Week (and Why It Looks Like a Good Value Now)
Shares in industrial software company PTC (PTC -9.84%) were lower by 8.8% in the week to Thursday afternoon. The move comes after a poorly received first-quarter 2025 earnings released on Wednesday.
